- Trials with a EudraCT protocol (127)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
127 result(s) found for: Gene flow.
Displaying page 1 of 7.
EudraCT Number: 2007-004308-11 | Sponsor Protocol Number: GTG002.07 | Start Date*: 2010-01-11 | |||||||||||
Sponsor Name:Genethon | |||||||||||||
Full Title: PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME | |||||||||||||
Medical condition: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopenia,... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001586-87 | Sponsor Protocol Number: RSLV-132-04 | Start Date*: 2016-09-29 |
Sponsor Name:Resolve Therapeutics, LLC | ||
Full Title: A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren’s Syndrome | ||
Medical condition: Primary Sjogrens Syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001019-22 | Sponsor Protocol Number: KAT-PAD101 | Start Date*: 2012-10-26 | |||||||||||
Sponsor Name:A.I.Virtanen Insitute, University of Kuopio | |||||||||||||
Full Title: Treatment of chronic critical lower limb ischemia with combination of surgical bypass operation and adenoviral VEGF-DdNdC intramuscular gene transfer A Randomized Single-Blinded Placebo-control... | |||||||||||||
Medical condition: Critical Chronic lower limb ischemia | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003895-65 | Sponsor Protocol Number: DAL-301 | Start Date*: 2016-06-22 | |||||||||||
Sponsor Name:DalCor Pharma UK Ltd, Leatherhead, Swiss Branch Zug | |||||||||||||
Full Title: A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Sy... | |||||||||||||
Medical condition: This study is investigating the cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects wit... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) SE (Completed) SK (Completed) DK (Completed) FI (Completed) PT (Completed) DE (Completed) HU (Completed) ES (Ongoing) AT (Completed) CZ (Completed) BG (Completed) RO (Ongoing) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002165-34 | Sponsor Protocol Number: RC19_0292 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:CHU of Nantes | |||||||||||||
Full Title: Predictive Signature of Benralizumab Response | |||||||||||||
Medical condition: Severe asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004370-55 | Sponsor Protocol Number: 2007-004370-55 | Start Date*: 2007-12-14 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial | |||||||||||||
Medical condition: CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), is a rare autosomal dominant disorder characterized by recurrent strokes starting in mid-adulth... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011152-22 | Sponsor Protocol Number: GTG003.08 | Start Date*: Information not available in EudraCT |
Sponsor Name:GENETHON | ||
Full Title: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome | ||
Medical condition: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome. An open labelled, non-randomised, phase I/II, cohort study involving a single infusion of autolo... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000517-33 | Sponsor Protocol Number: RP-L201-0318 | Start Date*: 2020-07-14 | |||||||||||
Sponsor Name:Rocket Pharmaceuticals, Inc. | |||||||||||||
Full Title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I):A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Len... | |||||||||||||
Medical condition: Leukocyte Adhesion Deficiency-I (LAD-I) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002680-26 | Sponsor Protocol Number: RP-L201-0218 | Start Date*: 2018-11-27 | |||||||||||
Sponsor Name:Rocket Pharmaceuticals, Inc. | |||||||||||||
Full Title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lenti... | |||||||||||||
Medical condition: Leukocyte Adhesion Deficiency-I (LAD-I) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022138-10 | Sponsor Protocol Number: FI.LU.VA | Start Date*: 2010-07-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: A SINGLE-CENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF COMBINATION THERAPY WITH VARDENAFIL 10 mg AND TAMSULOSIN 0,4 mg IN THE TREATMENT OF MEN WITH PER... | |||||||||||||
Medical condition: men with persistent irritative urinary symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006295-17 | Sponsor Protocol Number: MedTrace-002 | Start Date*: 2022-04-08 | |||||||||||
Sponsor Name:MedTrace Pharma | |||||||||||||
Full Title: A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O- H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Con... | |||||||||||||
Medical condition: Coronary Artery Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-005028-40 | Sponsor Protocol Number: MOLTO | Start Date*: 2019-08-29 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA | |||||||||||||
Full Title: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL | |||||||||||||
Medical condition: Richter syndrome of chronic lymphocytic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021430-64 | Sponsor Protocol Number: RR10/9389 | Start Date*: 2010-12-03 | |||||||||||
Sponsor Name:University of Leeds | |||||||||||||
Full Title: A randomised double blind placebo controlled clinical trial of anti B-cell therapy in patients with primary Sjögren’s syndrome. | |||||||||||||
Medical condition: Primary Sjögren’s syndrome (PSS). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004567-11 | Sponsor Protocol Number: 75911 | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Zealand University Hospital | |||||||||||||
Full Title: Effect of Low-dose Interferon-alfa2a on peri operative immune suppression | |||||||||||||
Medical condition: pMMR Colon cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005339-42 | Sponsor Protocol Number: N16HPV | Start Date*: 2016-08-30 |
Sponsor Name:NKI-AVL | ||
Full Title: Safety, immunogenicity and clinical response of sig-HELP-E6SH/E7SH-kdel, injected in the epidermis by DNA tattoo, in HPV16-positive vulvar intraepithelial neoplasia: a phase I/II study | ||
Medical condition: HPV16+ usual type vulvar intraepithelial neoplasia (uVIN) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000661-16 | Sponsor Protocol Number: CGRP2020 | Start Date*: 2020-06-18 | |||||||||||||||||||||
Sponsor Name:Rigshospitalet Glostrup | |||||||||||||||||||||||
Full Title: The effect of anti-calcitonin gene-related peptide (CGRP) receptor antibodies on the headache inducing properties of CGRP and cilostazol in migraine patients | |||||||||||||||||||||||
Medical condition: Migraine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004321-25 | Sponsor Protocol Number: NordDutchCML009 | Start Date*: 2013-04-03 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease af... | |||||||||||||
Medical condition: Chronic myeloid leukemia in chronic phase and ≥ 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level above 0.01% IS). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) SE (Completed) NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003261-18 | Sponsor Protocol Number: VITAL | Start Date*: 2019-11-22 |
Sponsor Name: | ||
Full Title: The effects of allergen immunotherapy on anti-viral immunity in patients with allergic asthma | ||
Medical condition: Allergic asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000137-52 | Sponsor Protocol Number: IFN-K-005-DM | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:Neovacs SA | |||||||||||||
Full Title: A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects with Dermatomyositis. | |||||||||||||
Medical condition: Dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002879-14 | Sponsor Protocol Number: BioVacSafe-Boostrix® | Start Date*: 2015-07-30 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: BioVacSafe-Boostrix®: een klinische studie om een reeks gegevens te regenereren die kenmerkend zijn voor klinische gebeurtenissen, fysiologische reacties en aangeboren en adaptieve immuunreacties v... | |||||||||||||
Medical condition: vaccin against diphtheria, tetanus and pertussis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
